You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》匯豐研究下調阿里健康(00241.HK)目標價至29元 評級「買入」
阿思達克 05-27 11:26
匯豐研究發表研報指,阿里健康(00241.HK)今年3月底止全年收入按年增長62%,較市場預測低約7%,淨利潤則較預測低22%,主要由於期內毛利率表現遜預期,按年持平在23.3%。

該行認為,主要由於期內處方藥銷售比例提高,產品組合調整導致利潤增長較預期低。年度自營及第三方電商銷售分別增長62%及68%,該行指出,阿里健康自營藥店未來將專注於藥物銷售,預期慢性疾病藥物將繼續是公司主要增長動力。

考慮到阿里健康持續拓展與藥企的合作,預期加大投資將令短期盈利能力提升,以及健康醫療料成未來發展趨勢,匯豐研究維持對阿里健康的「買入」評級,目標價由33.5元降至29元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account